title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Informed Consent Statement | Informed consent was obtained from all subjects involved in the study. | PMC10575211 | ||
Data Availability Statement | The authors confirm that the data supporting the findings of this study are available from the authors upon reasonable request. | PMC10575211 | ||
Conflicts of Interest | D.K., M.M. and A.P. (Anna Poświata) are employees of the EGZOTech company, which designed the Luna EMG robot. | PMC10575211 | ||
References | Participant upper limb position during elbow flexion/extension strength test (source—authors’ own).Study participant flowchart.Comparison of baseline and post-rehabilitation FIM results.Comparison of baseline and post-rehabilitation FIM motor subscale results.Participants’ characteristics at baseline.BMI—body mass inde... | PMC10575211 | ||
Background | weight loss, cardiovascular diseases | METABOLIC SYNDROME, TYPE 2 DIABETES, CARDIOVASCULAR DISEASES | Commercial smartphone apps that promote self-monitoring of weight loss are widely available. The development of disease-specific apps has begun, but there is no app for specific health guidance (SHG) to prevent metabolic syndrome, type 2 diabetes, and cardiovascular diseases in middle-aged adults in Japan. | PMC10134028 |
Objective | obesity, weight loss | OBESITY, HYPERTENSION | This study aimed to determine the efficacy of an SHG mobile health app in facilitating weight loss in Japanese adults with obesity and hypertension. | PMC10134028 |
Methods | personality traits, overweight, weight loss | OBESE | In a 12-week, statistician-blinded, randomized parallel controlled trial, 78 overweight and obese men aged 40-69 years were assigned in a 1:1 ratio to either the usual support plus KENPO-app group (intervention group) or the active control group. KENPO-app (release April 10, 2019; OMRON Healthcare Co., Ltd.) was develo... | PMC10134028 |
Results | ’s retention rate was 95% (74/78). | The trial’s retention rate was 95% (74/78). The adherence to daily self-weighing, wearing the pedometer, and blood pressure monitoring in the KENPO-app group was significantly higher than those in the active control group. Compared with the active control group, the median body weight and BMI of the intervention group ... | PMC10134028 | |
Conclusions | obesity, weight loss | OBESITY | The SHG-specific KENPO-app was feasible and induced modest but significant weight loss in adults with obesity. | PMC10134028 |
Trial Registration | University Hospital Medical Information Network Center UMIN000046263; https://tinyurl.com/bderys3b | PMC10134028 | ||
Introduction | cardiovascular diseases | METABOLIC SYNDROME, TYPE 2 DIABETES, CARDIOVASCULAR DISEASES | In 2008, all health insurers in Japan were mandated to provide specific health guidance (SHG) to prevent metabolic syndrome, type 2 diabetes, and cardiovascular diseases in middle-aged adults in Japan [ | PMC10134028 |
Methods | PMC10134028 | |||
Study Design | obesity | OBESITY, MAY, HYPERTENSION | This study was a 12-week, statistician-blinded, parallel-group, randomized controlled trial (RCT) of adults with obesity and hypertension. The data were obtained between October 2021 and May 2022. | PMC10134028 |
Ethics Approval | The study protocol was approved by the institutional review board of Kyoto Medical Center (NO.21-057), and the protocol of the study was registered at the University Hospital Medical Information Network Center (UMIN000046263). | PMC10134028 | ||
Participants | RECRUITMENT | Participants were recruited from the screening panel of the Omron monitor recruitment site for product development and research in Japan. Therefore, participants may have relatively higher computer/internet literacy. We held an online information session for this trial. Inclusion criteria were as follows: age 40-64 yea... | PMC10134028 | |
Randomization and Masking | The independent statistician randomly allocated participants into one of two intervention arms according to sex-, age-, SBP-, and BMI-stratified block randomization (seed=1221 and block size=2). We adopted a single-blind approach; thus, the effectiveness was assessed by blinded researchers who were unaware of the rando... | PMC10134028 | ||
Self-monitoring Tool | Participants in both groups received a Bluetooth weighing scale (HBF-227T, OMRON Healthcare Co, Ltd), pedometer (HJA-405T, OMRON Healthcare Co, Ltd), and upper arm blood pressure (BP) monitor (HCR-7501T, OMRON Healthcare Co, Ltd). | PMC10134028 | ||
The Active Control Group | The participants in the active control group received the usual support. The usual support was based on intensive SHG, and the participants in both groups received initial online face-to-face counseling by a health care professional (ie, a registered dietician) who had completed the established Ministry of Health, Labo... | PMC10134028 | ||
mHealth KENPO-app | personality traits, weight loss | KENPO-app (release April 10, 2019; OMRON Healthcare Co, Ltd) was developed using behavior change techniques (ie, self-monitoring and goal-setting theory) by the study team and focus groups. This app was developed for SHG based on the four specific health checkups and guidance system in Japan: (1) focusing on achieving ... | PMC10134028 | |
The contents of the KENPO-app study. | goals)Personality, weight loss |
Initial assessment (laboratory data, symptoms, and clinical goals)Personality traitSetting weight loss goalTargeting behavioral agenda (exercise, dietary, lifestyle habits, daily steps)
Pedometer, weight, and blood pressure, and behavioral agenda
SHG based on app data and personality trait
Pedometer, weight, and blood... | PMC10134028 | |
Outcome | The outcome included changes in body weight and BMI. Weight measurements were uploaded to the cloud where the data were obtained, and the 7-day average weight was calculated. Other outcomes included changes in SBP, DBP, and adherence to the device. The frequency of weight, BP, and step uploads was recorded as a measure... | PMC10134028 | ||
Statistical Analysis | Data are expressed as the mean (SD), median (IQR), range, or number. Blinded data were analyzed using the R software version 4.0.0. (R Foundation for Statistical Computing) on an intention-to-treat basis by the statistician. Statistical analysis of quantitative data was performed using the Shapiro-Wilk test, Mann-Whitn... | PMC10134028 | ||
Results | PMC10134028 | |||
Participants and Adherence | ATTRITION | After 80 participants were screened, we enrolled 78 participants and excluded 2. Of the 78 participants, the mean age was 52.0 (SD 6.5) years, and 55% (n=43) were male. Those who had full- and part-time jobs accounted for 65% (n=51) and 19% (n=15) of the sample, respectively. Participants were assigned to either the KE... | PMC10134028 | |
Healthy Behavior | The percentage of participants who reported ≥8000 steps per day, slow eating speed, vegetable intake before rice, selecting a healthy menu, and relaxation in the intervention group increased after the 12-week study period, while the percentage of eating breakfast and reducing snacks in the active control group increase... | PMC10134028 | ||
Discussion | PMC10134028 | |||
Principal Findings | weight loss, diabetes [ | OBESE, HYPERTENSION | This is the first study to confirm the effectiveness of the SHG-specific KENPO-app in obese adults with hypertension. The mHealth KENPO-app is feasible and can produce modest but significant weight loss. Compared with standard care, the mHealth app produced modest weight loss (–1.0 kg to –2.4 kg of body weight) in obes... | PMC10134028 |
Adherence and Weight Change | weight loss | Self-monitoring of weight was a significant predictor of weight loss [ | PMC10134028 | |
Healthy Behavior and Weight Loss | obesity | OBESITY | The current consensus states that obtaining less than 5000 steps per day is sedentary behavior, whereas obtaining >8000 steps indicates an active exercise habit [Moreover, slow eating speed, vegetable intake before rice, selection of a healthy menu, and relaxation in the intervention group increased after the intervent... | PMC10134028 |
Personality Traits and Weight Changes | weight loss | Personality traits are an important factor in health behaviors. Interestingly, personality traits were associated with the degree of weight change in this study. Specific aspects of personality (ie, agreeableness) are relevant to weight loss maintenance [ | PMC10134028 | |
Strength and Limitations | obesity, weight loss | OBESITY, HYPERTENSION | The strengths of this study include the SHG-specific mHealth app, objective measurement of data, and a high retention rate. Although mHealth apps for weight management are popular and widely available, many apps lack professional content expertise. Encouraging app development based on evidence-based online approaches w... | PMC10134028 |
Abbreviations | blood pressurediastolic blood pressureinformation and communications technologymobile healthMinistry of Health, Labor and Welfarerandomized controlled trialsystolic blood pressurespecific health guidance | PMC10134028 | ||
Materials and methods | PMC10426956 | |||
Overview | OSF | Prior to beginning our study, we secured approval to carry out our research through the Grand Valley State University institutional review board (Protocol 21-248-H, written consent obtained via online survey). Data and materials for our research are available via OSF at Participants were asked to complete the reference... | PMC10426956 | |
Participants | Responses were received from 436 individuals in supervisory positions. Prior to data analysis, we screened for insufficient effort responding (IER) [ | PMC10426956 | ||
Procedure | Participants were asked to reflect upon the employee they least like to work with in their primary job, after which they were presented with the following instructions, which were inspired by instructions used by König and colleagues [Imagine that the employee you’ve been asked to think about had to leave their job for... | PMC10426956 | ||
Measures | The following focal measures were completed by participants after the aforementioned instructions, and they were presented in random order. Additional questions commonly found in reference checks were included to enhance the realism of the reference check (e.g., “Would you rehire the applicant?”), although they were no... | PMC10426956 | ||
Fear of adverse consequences | Although researchers have studied fear of adverse consequences in performance management contexts [Items measuring fear of legal consequences included: “Worried about being sued for defamation of character by the applicant because of the reference check”, “Concerned that the applicant might file a lawsuit against me be... | PMC10426956 | ||
Applicant workplace incivility | Blau and Andersson’s [ | PMC10426956 | ||
Manipulation checks | We used factual manipulation checks to assess their effectiveness [ | PMC10426956 | ||
Interaction between applicant consent and qualified privilege reminders in relation to fear of adverse legal consequences. | PMC10426956 | |||
Interaction between confidentiality and qualified privilege reminders in relation to applicant workplace incivility. | PMC10426956 | |||
Discussion | We sought to apply signaling theory to experimentally test whether three signals (reminders) sent to reference providers could decrease their fear and increase their reporting of applicant workplace incivility. Below we summarize the theoretical implications and limitations of our study, as well as the practical implic... | PMC10426956 | ||
Implications for theory, research, and practice | SAID | Our study offers implications for the literature on reference checks. First, it is important to note that the signals and their interactions explained only a small amount of variability in reference provider’s fear of adverse consequences and reports of applicant workplace incivility. We found no evidence for direct ef... | PMC10426956 | |
Limitations and future research directions | Our study has several limitations that should be considered by readers as they interpret our findings. First, our study involved a hypothetical reference check. We believe this approach was necessary for the ethical reasons we described earlier; namely, that manipulating the reference checking process for actual job ap... | PMC10426956 | ||
Supporting information | PMC10426956 | |||
STROBE statement—checklist of items that should be included in reports of observational studies. | (DOCX)Click here for additional data file. | PMC10426956 | ||
References | PMC10426956 | |||
Subject terms | pain | Symptomatic, partial-thickness rotator cuff tears (sPTRCT) are problematic. This study tested the hypothesis that management of sPTRCT with injection of fresh, uncultured, unmodified, autologous, adipose-derived regenerative cells (UA-ADRCs) is safe and more effective than injection of corticosteroid even in the long r... | PMC10630470 | |
Introduction | shoulder pain | OXIDATIVE STRESS | Symptomatic, partial-thickness rotator cuff tear (sPTRCT) is a common cause of shoulder pain, loss of function and occupational disabilityCurrent non-surgical and surgical treatment options to address sPTRCT do not offer the potential to naturally replace damaged tendon tissue and often do not improve clinical results.... | PMC10630470 |
Methods | PMC10630470 | |||
Study design | The present study was a long term follow-up study of a first-in-human, two center, prospective, open-label, randomized controlled trialFigure Flow of subjects in the present and the former studies | PMC10630470 | ||
Ethics | The present study received Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) on 13/05/2019 (no. 16956), received Institutional Review Board (IRB) approval from WIRB Copernicus Group, Inc. (Olympia, WA, USA) on 23/07/2019 for study site Sanford USD Medical Center, Sioux Falls, SD, U... | PMC10630470 | ||
Outcome measurements and assessments | pain | ADVERSE EVENTS, EVENTS | According to the study protocol the primary endpoints of the present study were long-term safety as indicated through the rate of treatment emergent adverse events (TEAEs), and long-term efficacy of pain and function through American Shoulder and Elbow Surgeons Standardized Shoulder Assessment FormAdverse events in the... | PMC10630470 |
Analysis of MRI scans | PD | Next to the determination of the partial-thickness tear size (calculated as ellipsoid volume), the proton density weighted, fat saturated, T2-weighted (PD FS T2) coronal MRI scans of all subjects who were enrolled in the present study were transferred in digital and fully anonymized form (compliant with the HIPAA regul... | PMC10630470 | |
Estimand strategies for handling intercurrent events | EVENTS | In line with the new In short, in case of treatment failures (comprising all intercurrent events that required additional injections of corticosteroid into the index shoulder or surgery of the index shoulder that were definitely, probably or possibly related to the study treatments, including development of a full-thic... | PMC10630470 | |
Statistical analysis | TEAEs, pain | Statistical analysis of the safety data included group-specific comparisons of the following variables: (i) total number of TEAEs, (ii) number of TEAEs experienced per subject, (iii) number of TEAEs classified as {mild/moderate/severe}, (iv) relationship of TEAEs to treatment classified as {not related/unlikely/possibl... | PMC10630470 | |
Results | PMC10630470 | |||
Long-term safety of treating sPTRCT with injection of either UA-ADRCs or corticosteroid | TEAEs | The subjects in the UA-ADRCs group reported a total number of 58 TEAEs (35 TEAEs during the former studyNo TEAE that occurred during the present and the former studiesAll subjects reported experiencing at least one TEAE. The number of subjects who experienced 1/2/3/4/6/7/8/10/12 TEAEs in the present and the former stud... | PMC10630470 | |
Long-term efficacy of treating sPTRCT with injection of either UA-ADRCs or corticosteroid | Pain, pain | Four of the 11 subjects (36.4%) in the UA-ADRCs group and three of the five subjects (60.0%) in the corticosteroid group developed additional pathologies of the index shoulder (next to sPTRCT) and/or received additional injections into or surgery of the index shoulder (next to injection of either UA-ADRCs or corticoste... | PMC10630470 | |
Partial thickness rotator cuff tear size as a function of time after treatment with injection of either UA-ADRCs or corticosteroid | The individual tear size as a function of time post-treatment is shown in Supplementary Fig. | PMC10630470 | ||
Detection of hyperintense structures on PD FS T2 coronal MRI scans of the index shoulder at the position of the supraspinatus tendon after injection of UA-ADRCs, but not after injection of corticosteroid, at 24 weeks post-treatment but not at baseline | The PD FS T2 coronal MRI scans of the index shoulder of 10 of 11 subjects (90.9%) in the UA-ADRCs group and none of the subjects (0%) in the corticosteroid group showed hyperintense structures at the position of the supraspinatus tendon at W24 post-treatment but not at baseline. A representative example is shown in Fig... | PMC10630470 | ||
No relationship between treatment outcome and baseline data | Supplementary Figs. | PMC10630470 | ||
Conclusions | The present investigation further supports treatment of sPTRCT with injection of UA-ADRCs. Once this therapy is approved in the US, clinicians should consider injection of UA-ADRCs instead of injection of corticosteroids. In the long run treatment of sPTRCT with injection of UA-ADRCs may delay or even prevent surgical ... | PMC10630470 | ||
Supplementary Information | The online version contains supplementary material available at 10.1038/s41598-023-46653-4. | PMC10630470 | ||
Acknowledgements | We thank the personell at Sanford Orthopedics and Sports Medicine Fargo (Fargo, ND, USA), Sanford Orthopedics and Sports Medicine Sioux Falls (Sioux Falls, SD, USA) and Sanford Radiology Clinic (Sioux Falls, SD, USA) for skillful assistance in this study. | PMC10630470 | ||
Author contributions | N.M. | M.L. screened and treated subjects, and edited the manuscript. J.H. screened and treated subjects, and edited the manuscript. M.H. analyzed MRI scans and edited the manuscript. M.H. analyzed MRI scans and edited the manuscript. T.R.F. participated in conceptualization and data curation, and edited the manuscript. J.P.F... | PMC10630470 | |
Data availability | The datasets used and analyzed during the current study are available from the corresponding author on reasonable request, taking into account any confidentiality. | PMC10630470 | ||
Competing interests | C.A. is Director of Medical and Scientific Affairs of InGeneron, Inc. (Houston, TX, USA). E.U.A. is Executive Chair of InGeneron. C.S. is Advisory Medical Director of InGeneron. However, InGeneron had no role in study design, data collection and analysis, interpretation of the data, and no role in the decision to publi... | PMC10630470 | ||
References | PMC10630470 | |||
Subject terms | inflammation | INFLAMMATION, DISEASE | Inflammatory response in COVID-19 contributes greatly to disease severity. Mesenchymal Stem Cells (MSCs) have the potential to alleviate inflammation and reduce mortality and length of stay in COVID-19 patients. We investigated the safety and effectiveness of normoxic-allogenic umbilical cord (NA-UC)-MSCs as an adjunct... | PMC10397314 |
Introduction | DISEASE, CORONAVIRUS DISEASE 2019, INFLAMMATORY RESPONSE | The emergence of the Coronavirus disease 2019 (COVID-19) pandemic has highlighted the need for streamlined drug development and validation within a condensed timeframeThe severity of the disease is not determined by the SARS-CoV-2 viral load but rather by the inflammatory response, which may be quantified in plasma sam... | PMC10397314 | |
Results | PMC10397314 | |||
Recruitment | RECRUITMENT, RECRUITMENT | Recruitment patients using both the Indonesian Ministry of Health guidelines on COVID-19 and Wu Z, McGoogan JM criteria were consulted for severe COVID-19 categorisationParticipant recruitment process. | PMC10397314 | |
General subject characteristics | The general comparison between the NA-UC-MSCs and the placebo groups was summarised in Table General Characteristics of Participants.Note: NA-UC-MSCs (normoxic-allogenic umbilical cord mesenchymal stem cells). | PMC10397314 | ||
Duration of hospitalisation | The average hospital stay in subjects who received NA-UC-MSCs was 20.81 ± 12.25 days compared to control subjects, who were treated for 16.81 ± 5.63 days as shown in Table Duration of Hospitalisation (Days) Since Admission.* Normal distribution, | PMC10397314 | ||
Radiographical severity (Brixia score) | Table Brixia score between groups.Variables were presented as median (IQR). *Mean Brixia scores at days 0, 15, and 22 of treatment. | PMC10397314 | ||
MMRC dyspnoea scale, PEF, and 6 MW test | dyspnoea | Table MMRC dyspnoea scale over time across groups.Note: NA-UC-MSCs (normoxic-allogenic umbilical cord mesenchymal stem cells).* MMRC dyspnoea scale in the intervention and control groups.PEF and 6 MW distance (m) between two groups.Variables were presented as median (IQR). *Significant values are in [bold].PEF and 6 MW... | PMC10397314 | |
PCT, ESR, and CRP markers | PCT | Table Oxygen index, duration oxygenation, and O2 saturation across group.Oxygen index, and OSignificant values are in [bold].Oxygenation index and oxygen saturation across both treatment groups.Table PCT, ESR and CRP level across groups.Variables were presented as median (IQR). *Significant values are in [bold].Evoluti... | PMC10397314 | |
Survival | A total of 14 subjects (33.3%) were deceased during the course of therapy. Among those who died, seven (16.7%) were in the NA-UC-MSCs group, and the other seven (16.7%) were from the control group. These subjects were then classified as "early terminated" patients. | PMC10397314 | ||
Discussion | inflammation, bacterial co-infection, pneumonia, dyspnoea | PNEUMONIA, PCT, INFLAMMATION, DISEASE, RESPIRATORY FAILURE, SKIN BACTERIAL INFECTION | The intravenous administration of NA-UC-MSCs did not affect the duration of hospitalization in severe COVID-19 patients. This study, however, confirmed the safety of NA-UC-MSCs therapy in these subjects. We choose the duration of stay in the hospital as the primary outcome since we want to clarify previously study that... | PMC10397314 |
Methodology | PMC10397314 | |||
Study design | This study was a multicentric, double-blinded, randomized, placebo-controlled trial to evaluate NA-UC-MSCs as a complementary treatment in severe COVID-19 patients (clinicaltrials.gov registration number NCT05132972 24/11/2021). This study approved by Health Research Ethics Committee, National Institute of Health Resea... | PMC10397314 | ||
Participants | ovarian cancer, shock, breast cancer, organ failure, tumors | OVARIAN CANCER, RECRUITMENT, SHOCK, BREAST CANCER, TUMORS, COMPLICATIONS | Subjects were picked via stratified random sampling, then randomized via a computerized random number generator. The total number of subjects was 42, divided into 21 subjects in the NA-UC-MSCs group and 21 in the placebo (NaCl) group. They hail from three major hospitals across the island of Java: Dr. Hasan Sadikin Gen... | PMC10397314 |
Randomization and masking | All eligible subjects (n = 42) were randomly assigned into two groups (1:1 ratio) to either the intervention group, who were to receive NA-UC-MSCs (n = 21), or the placebo group, who were administered with NaCl (n = 21). Randomization was performed using blocks (block size = 4), and subjects were assigned to both group... | PMC10397314 | ||
NA-UC-MSCs preparation | Bifarma, infectious disease, HIV, Hepatitis B | INFECTIOUS DISEASE, SYPHILIS, HEPATITIS C | Human umbilical cords were obtained from the cesarean section in the maternity ward of a hospital in Jakarta from a qualified donor that passed donor screening and testing of infectious disease (HIV, Hepatitis B, Hepatitis C, Syphilis, CMV IgM) and karyotyping. The human umbilical cord was subsequently processed to yie... | PMC10397314 |
Intervention | dyspnea | PCT | Before the administration of either MSCs or placebo, history-taking and physical examination [including the Modified Medical Research Council (mMRC) dyspnea scale], routine hematological testing, inflammatory marker testing [procalcitonin (PCT), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)], chest X-r... | PMC10397314 |
Outcomes | PMC10397314 | |||
Primary outcome | The primary outcome of this trial was the subjects' duration of hospitalization. | PMC10397314 | ||
Secondary outcome | Dyspnea | ADVERSE EVENTS, SECONDARY, PCT | The secondary outcomes of this trial were radiological and clinical indicators on baseline (day 0–2), 15 (± 2), and 22 (± 2) days: (1) Brixia score for radiographic severity; (2) mMRC Dyspnea scale; (3) oxygenation index; (4) duration of oxygen therapy (days); (5) peripheral oxygen saturation; (6) 6 MW test; (7) PEF; (... | PMC10397314 |
Sample collection | Peripheral venous blood samples | BLOOD, SECONDARY, PCT | Peripheral venous blood samples were collected for PCT, ESR, and CRP level assessment. Blood was collected on days 0–2 (baseline), 15 (± 2), and 22 (± 2) after the intervention. Following extraction, sample tubes were secured into primary (zip-lock bag), secondary (insulated bottles), and tertiary packs (insulated box ... | PMC10397314 |
Statistical analysis | All data in this trial were analyzed with the software SPSS V.22 (IBM). For categorical variables, analyses were computed using the χ-square or Fisher's exact test. For unpaired continuous quantities, either an independent-sample T-test (normal distribution) or an independent-sample Mann–Whitney U test (non-normal dist... | PMC10397314 | ||
Conclusion | DISEASES, PCT | Although we have failed to demonstrate the reduction in the length of stay of severe COVID-19 patients with NA-UC-MSCs therapy, we have established that it is a very safe adjunct that yielded no AE, including serious ones, for at least 91 days after the first dose. NA-UC-MSCs therapy also did not reduce the Brixia scor... | PMC10397314 | |
Supplementary Information | The online version contains supplementary material available at 10.1038/s41598-023-39268-2. | PMC10397314 | ||
Acknowledgements | Bifarma | This study was supported by the Grants-in-Aid from The National Research and Innovation Agency (BRIN) Indonesia and PT. Bifarma Adiluhung, Jakarta, Indonesia. | PMC10397314 | |
Author contributions | B.S., R.G.M., A.N. and A.F. designed the study. B.S. as national coordinator; R.G.M., A.N. and A.F. as PI for each center; R.G.M., J.A.T. and A.F. performed statistical analyses and drafted the manuscript. B.S. and A.N. team in Solo site are Pur., A.A., B.R.A.S., and W.S.; R.G.M. team in Yogyakarta site are Sum., Sud.,... | PMC10397314 | ||
Funding | Bifarma | Badan Riset dan Inovasi Nasional, No. 94/FI/P-KCOVID-19.2B3/IX/2020, No. 94/FI/P-KCOVID-19.2B3/IX/2020, No. 94/FI/P-KCOVID-19.2B3/IX/2020, No. 94/FI/P-KCOVID-19.2B3/IX/2020, No. 94/FI/P-KCOVID-19.2B3/IX/2020, No. 94/FI/P-KCOVID-19.2B3/IX/2020, No. 94/FI/P-KCOVID-19.2B3/IX/2020, No. 94/FI/P-KCOVID-19.2B3/IX/2020, No. 94... | PMC10397314 | |
Data availability | The datasets generated during and/or analysed during the current study are not publicly available due to confidential data of the patients but are available from the corresponding author on reasonable request. | PMC10397314 | ||
Competing interests | The authors declare no competing interests. | PMC10397314 | ||
References | PMC10397314 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.